Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares rose 22.9% during mid-day trading on Thursday . The stock traded as high as $3.24 and last traded at $3.17. Approximately 2,567,450 shares were traded during trading, an increase of 66% from the average daily volume of 1,544,165 shares. The stock had previously closed at $2.58.

The stock has a market cap of $3.95 million, a P/E ratio of -0.11 and a beta of 1.85.

A number of institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. purchased a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $34,000. CVI Holdings LLC acquired a new position in Tonix Pharmaceuticals in the 4th quarter valued at about $36,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth about $38,000. 34.30% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at

About Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.

Recommended Story: Return On Assets

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.